The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
Status:
Withdrawn
Trial end date:
2020-04-20
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, blank-controlled treatment clinical study. The objective
of this study is to investigate the effect of T89 on improving oxygen saturation and clinical
symptoms in patients with Coronavirus Disease 2019 (COVID-19). In this study, estimated total
of 120-240 male and female patients who have been diagnosed with non-critical type of
coronavirus pneumonia (COVID-19) will be enrolled and randomly assigned to one of two study
groups, the T89 treatment group and the blank control group, to T89 or nothing on the base of
a recommended standard treatment for up to 14 days . The primary efficacy parameters include
the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients
with normal level of oxygen saturation after treatment, and the total duration of oxygen
inhalation, oxygen flow change by time, oxygen concentration change by time during treatment.